biostudies-literatureWallwiener MNovartis Pharma611https://www.ebi.ac.uk/biostudies/studies/S-EPMC6588890biostudies-literatureUnknown19(1)<h4>Background</h4>Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients.<h4>Methods</h4>EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor-positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT.<h4>Results</h4>Out of 20BMC cancerInfluence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.PMC6588890not applicableWuerstlein RHarbeck NHeyl VKohls AFeisst MBaake GMundhenke CWachsmann GBayer CMVollert HWSchmidt KHenschen SThomssen CDeuker JUWarm MBrucker SYBrucker CRezai MBaier BKrauss TKummel SNabieva NTesch Hde Waal JFasching PARezek DLandthaler RPraetz TSiebers JWBelleville EFischer GHein ARauh CHartkopf AGuggenberger MPopovic MBreitbach GPWolf CNoesselt TKuhn TBeckmann MWKolberg HCRichter BDall PHadji PHohn AWallwiener DFehm TWallwiener MJanni WfalseInfluence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study.<h4>Background</h4>Treatment of postmenopausal, hormone receptor-positive metastatic breast cancer (MBC) patients varies despite clear therapy guidelines, favoring endocrine treatment (ET). Aim of this study was to analyze persistence of palliative aromatase inhibitor (AI) monotherapy in MBC patients.<h4>Methods</h4>EvAluate-TM is a prospective, multicenter, noninterventional study to evaluate treatment with letrozole in postmenopausal women with hormone receptor-positive breast cancer. To assess therapy persistence, defined as the time from therapy start to the end of the therapy (TTEOT), two pre-specified study visits took place after 6 and 12 months. Competing risk survival analyses were performed to identify patient and tumor characteristics that predict TTEOT.<h4>Results</h4>Out of 202019-01-01T00:00:00Z2019 Jun2025-04-04T19:00:00.361Z2019-07-24T07:26:21ZS-EPMC65888903122702510.1186/s12885-019-5806-y